Wu Yang Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wu Yang Zhu has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Shu Qing Liu
Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, NHC Key Laboratory of Biosafety, Chinese Center for Disease Control and Prevention, Beijing, P. R. China
8 shared publications Yuan Xie
Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, NHC Key Laboratory of Biosafety, Chinese Center for Disease Control and Prevention, Beijing, P. R. China
5 shared publications- Xiao-Yan Tao
Key Laboratory for Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
4 shared publications Ying Lin Chi
Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, NHC Key Laboratory of Biosafety, Chinese Center for Disease Control and Prevention, Beijing, P. R. China
3 shared publications- Charles E. Rupprecht
College of Forestry, Wildlife and Environment, Auburn University, Auburn, AL 36849, USA
2 shared publications - Eric Tsao
Synermore Biologics (Suzhou) Co., Ltd., Suzhou, China
2 shared publications
Latest Publications
- Open Access
SYN023, a Humanized Monoclonal Antibody Cocktail, Broadly Neutralizes Genetically Diverse Lyssaviruses and Validates Epitope Prediction Accuracy
Background/Objectives: Lyssaviruses pose a persistent global public health threat, underscoring the need for broad-spectrum neutralizing antibodies to improve rabies post-exposure prophylaxis (PEP). The humanized monoclonal antibody cocktail SYN023 is approved for PEP in China and under active global regulatory review. This study aimed to validate pseudovirus-based neutralization assays, verify SYN023 epitope prediction accuracy, and systematically characterize its pan-lyssavirus neutralizing activity. Methods: Assay validation was performed by directly comparing neutralization titers obtained with authentic rabies virus (RABV) and pseudotyped virus. Epitope analysis was performed, followed by in vivo evaluation in a canine PEP challenge model. The pseudovirus-based neutralization assay was used to assess SYN023 broad-spectrum activity across diverse lyssaviruses. Results: Neutralization titers from authentic and pseudotyped viruses showed high concordance (R2 = 0.8341, p < 0.0001), supporting the pseudovirus system as a reliable surrogate assay. Epitope analysis confirmed that SYN023’s epitope is fully conserved in the highly virulent New York City (NYC) RABV strain. In canine PEP challenge studies using the NYC strain, SYN023 conferred strong protection at 0.1–0.5 mg/kg. SYN023 exhibited potent neutralizing activity against phylogenetically diverse non-rabies lyssaviruses, including Mokola virus (MOKV; EC50 = 14.74 µg/mL), whereas three clinically validated reference antibodies failed to neutralize MOKV even at concentrations up to 1000 µg/mL. Conclusions: This study demonstrates that the pseudovirus-based neutralization assay is a reliable surrogate assay. It also confirms the functional accuracy of the epitope mapping strategy and demonstrates the broad neutralization spectrum of SYN023 against a diverse panel of lyssaviruses.
Open AccessSYN023, a Humanized Monoclonal Antibody Cocktail, Broadly Neutralizes Genetically Diverse Lyssaviruses and Validates Epitope Prediction Accuracy
Background/Objectives: Lyssaviruses pose a persistent global public health threat, underscoring the need for broad-spectrum neutralizing antibodies to improve rabies post-exposure prophylaxis (PEP). The humanized monoclonal antibody cocktail SYN023 is approved for PEP in China and under active global regulatory review. This study aimed to validate pseudovirus-based neutralization assays, verify SYN023 epitope prediction accuracy, and systematically characterize its pan-lyssavirus neutralizing activity. Methods: Assay validation was performed by directly comparing neutralization titers obtained with authentic rabies virus (RABV) and pseudotyped virus. Epitope analysis was performed, followed by in vivo evaluation in a canine PEP challenge model. The pseudovirus-based neutralization assay was used to assess SYN023 broad-spectrum activity across diverse lyssaviruses. Results: Neutralization titers from authentic and pseudotyped viruses showed high concordance (R2 = 0.8341, p < 0.0001), supporting the pseudovirus system as a reliable surrogate assay. Epitope analysis confirmed that SYN023’s epitope is fully conserved in the highly virulent New York City (NYC) RABV strain. In canine PEP challenge studies using the NYC strain, SYN023 conferred strong protection at 0.1–0.5 mg/kg. SYN023 exhibited potent neutralizing activity against phylogenetically diverse non-rabies lyssaviruses, including Mokola virus (MOKV; EC50 = 14.74 µg/mL), whereas three clinically validated reference antibodies failed to neutralize MOKV even at concentrations up to 1000 µg/mL. Conclusions: This study demonstrates that the pseudovirus-based neutralization assay is a reliable surrogate assay. It also confirms the functional accuracy of the epitope mapping strategy and demonstrates the broad neutralization spectrum of SYN023 against a diverse panel of lyssaviruses.
- Open Access
- 3 September 2026
- Published by MDPI AG in Preprints.org
SYN023, a Humanized Monoclonal Antibody Cocktail, Broadly Neutralizes Genetically Diverse Lyssaviruses and Validates Epitope Prediction Accuracy
Background: Lyssaviruses remain a global public health threat, requiring broad-spectrum, high-potency neutralizing antibodies as part of recommended human rabies post-exposure prophylaxis (PEP). A humanized monoclonal antibody cocktail, SYN023, is approved for PEP in China and is under global regulatory review. Its epitope mapping data are promising. However, the neutralization breadth across diverse lyssaviruses and the reliability of pseudovirus-based neutralization assays still require comprehensive validation to support worldwide regulatory approval and clinical use. Methods: First, the correlation between authentic lyssaviruses virus and pseudotyped viruses neutralization was established experimentally to verify the reliability of the pseudovirus-based neutralization assay. Second, epitope mapping was performed using a highly virulent rabies virus (RABV) variant (New York City strain: NYC) provided by the U.S. Department of Agriculture, followed by in vivo PEP efficacy studies in a standardized canine model to functionally validate the mapped epitopes. Third, the neutralizing activity of SYN023 was evaluated against a phylogenetically diverse panel of non-RABV lyssaviruses and directly benchmarked against clinically validated comparator monoclonal antibodies, thereby providing robust, quantitative empirical evidence supporting its broad-spectrum neutralization capability. Results: A strong positive correlation was observed between neutralization titers elicited by authentic lyssaviruses and pseudotyped viruses (Pearson R2 = 0.83, P < 0.0001), validating the pseudovirus-based assay as a robust surrogate for authentic virus neutralization. Specifically, SYN023 recognized and potently neutralized the epitope mapped on the prototypic NYC RABV strain. The in vivo PEP studies conducted in a standardized canine challenge model, using the NYC strain as the challenge virus, demonstrated high protective efficacy at SYN023 doses ranging from 0.1 to 0.5 mg/kg. Furthermore, SYN023 exhibited broad, potent, and reproducible neutralizing activity against a phylogenetically diverse panel of non-RABV lyssaviruses, including European bat lyssavirus 1 (EBLV1), European bat lyssavirus 2 (EBLV2), Australian bat lyssavirus (ABLV), Bokeloh bat lyssavirus (BBLV), Taiwan bat lyssavirus 1 (TWBLV1), Taiwan bat lyssavirus 2 (TWBLV2), Kotalahti bat lyssavirus (KBLV), Divača bat lyssavirus (DBLV), Gannoruwa bat lyssavirus (GBLV), Duvenhage virus (DUVV), Khujand virus (KHUV), Aravan virus (ARAV), Mokola virus (MOKV), Lagos bat virus (LBV) and Shimoni bat virus (SHIBV). Notably, SYN023 achieved robust neutralization of MOKV (EC50 = 14.74 µg/mL), whereas clinically referenced monoclonal antibodies—Rabishield, Ormutivimab and GR1801—exhibited no detectable neutralizing activity against MOKV even at concentrations up to 1,000 µg/mL. This pan-lyssavirus neutralizing capacity was attributable mechanistically to SYN023’s targeting of a highly conserved conformational epitope within the viral glycoprotein, which is structurally preserved across all major lyssavirus phylogroups. Conclusion: This study demonstrated that the pseudovirus-based neutralization assay is a reliable surrogate platform. In addition, it confirmed the functional accuracy of the epitope mapping strategy, showed the protective efficacy against a virulent RABV challenge in dogs, and demonstrated the broad neutralization spectrum of the SYN023 antibody cocktail against both RABV and a phylogenetically diverse panel of non-RABV lyssaviruses.
- 3 September 2026
- Published by MDPI AG in Preprints.org
Open AccessSYN023, a Humanized Monoclonal Antibody Cocktail, Broadly Neutralizes Genetically Diverse Lyssaviruses and Validates Epitope Prediction Accuracy
Background: Lyssaviruses remain a global public health threat, requiring broad-spectrum, high-potency neutralizing antibodies as part of recommended human rabies post-exposure prophylaxis (PEP). A humanized monoclonal antibody cocktail, SYN023, is approved for PEP in China and is under global regulatory review. Its epitope mapping data are promising. However, the neutralization breadth across diverse lyssaviruses and the reliability of pseudovirus-based neutralization assays still require comprehensive validation to support worldwide regulatory approval and clinical use. Methods: First, the correlation between authentic lyssaviruses virus and pseudotyped viruses neutralization was established experimentally to verify the reliability of the pseudovirus-based neutralization assay. Second, epitope mapping was performed using a highly virulent rabies virus (RABV) variant (New York City strain: NYC) provided by the U.S. Department of Agriculture, followed by in vivo PEP efficacy studies in a standardized canine model to functionally validate the mapped epitopes. Third, the neutralizing activity of SYN023 was evaluated against a phylogenetically diverse panel of non-RABV lyssaviruses and directly benchmarked against clinically validated comparator monoclonal antibodies, thereby providing robust, quantitative empirical evidence supporting its broad-spectrum neutralization capability. Results: A strong positive correlation was observed between neutralization titers elicited by authentic lyssaviruses and pseudotyped viruses (Pearson R2 = 0.83, P < 0.0001), validating the pseudovirus-based assay as a robust surrogate for authentic virus neutralization. Specifically, SYN023 recognized and potently neutralized the epitope mapped on the prototypic NYC RABV strain. The in vivo PEP studies conducted in a standardized canine challenge model, using the NYC strain as the challenge virus, demonstrated high protective efficacy at SYN023 doses ranging from 0.1 to 0.5 mg/kg. Furthermore, SYN023 exhibited broad, potent, and reproducible neutralizing activity against a phylogenetically diverse panel of non-RABV lyssaviruses, including European bat lyssavirus 1 (EBLV1), European bat lyssavirus 2 (EBLV2), Australian bat lyssavirus (ABLV), Bokeloh bat lyssavirus (BBLV), Taiwan bat lyssavirus 1 (TWBLV1), Taiwan bat lyssavirus 2 (TWBLV2), Kotalahti bat lyssavirus (KBLV), Divača bat lyssavirus (DBLV), Gannoruwa bat lyssavirus (GBLV), Duvenhage virus (DUVV), Khujand virus (KHUV), Aravan virus (ARAV), Mokola virus (MOKV), Lagos bat virus (LBV) and Shimoni bat virus (SHIBV). Notably, SYN023 achieved robust neutralization of MOKV (EC50 = 14.74 µg/mL), whereas clinically referenced monoclonal antibodies—Rabishield, Ormutivimab and GR1801—exhibited no detectable neutralizing activity against MOKV even at concentrations up to 1,000 µg/mL. This pan-lyssavirus neutralizing capacity was attributable mechanistically to SYN023’s targeting of a highly conserved conformational epitope within the viral glycoprotein, which is structurally preserved across all major lyssavirus phylogroups. Conclusion: This study demonstrated that the pseudovirus-based neutralization assay is a reliable surrogate platform. In addition, it confirmed the functional accuracy of the epitope mapping strategy, showed the protective efficacy against a virulent RABV challenge in dogs, and demonstrated the broad neutralization spectrum of the SYN023 antibody cocktail against both RABV and a phylogenetically diverse panel of non-RABV lyssaviruses.
- 16 July 2026
- Published by Elsevier in Journal of Virological Methods
- Vol. 346, 115437
Stability analysis of rabies virus in the environment
- 16 July 2026
- Published by Elsevier in Journal of Virological Methods
- Vol. 346, 115437
Stability analysis of rabies virus in the environment
- Open Access
- 29 April 2026
- Published by Springer Nature in Virology Journal
- Vol. 23 (1)
MG132-mediated inhibition of rabies virus replication via the Nrf2/SQSTM1/PINK1/Parkin autophagy pathway
Rabies virus (RABV), a fatal neurotropic virus, still lacks effective antiviral drugs for treatment once symptoms appear. MG132 acts as a novel therapeutic
- 29 April 2026
- Published by Springer Nature in Virology Journal
- Vol. 23 (1)
Open AccessMG132-mediated inhibition of rabies virus replication via the Nrf2/SQSTM1/PINK1/Parkin autophagy pathway
Rabies virus (RABV), a fatal neurotropic virus, still lacks effective antiviral drugs for treatment once symptoms appear. MG132 acts as a novel therapeutic
- Open Access
- 13 September 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-9
Epidemiological characteristics of human rabies cases reported by sites in China from 2006 to 2022
Rabies is an incessant public health threat in China. The Ministry of Health implemented the Central Payment for Rabies Prevention and Control Project to assist with rabies prevention and control in a few representative provinces in 2006. Data on human rabies cases reported by the National Infectious Disease Reporting Information Management System and national surveillance sites from 2006 to 2022 were collected, and statistical and multivariate analyses were then used to assess the effectiveness of current prevention and control efforts. During 2006–2022, a total of 2025 human rabies cases were collected by the national surveillance sites, with incidence rates far above the national average, but the incidence rate was consistent with the national trend. Human rabies cases demonstrated a dual peak distribution in terms of exposure and onset dates, with the peak exposure dates falling mostly in the spring and summer and the peak onset dates occurring mostly in the summer and autumn. Three danger categories are shown by the geographical distribution: high, medium and low. Dogs had a high infection rate (86.93%), with own domesticated dogs accounting for the majority of infections. The rates of post-exposure prophylaxis are not constant. The median incubation period was 71 days. Various measures and policies implemented by the government have played a key role in reducing the incidence of rabies. To effectively prevent and control the resurgence of epidemics and halt the spread of the virus among host animals, it is imperative to prioritize and implement a robust dog management system, accelerate research and development of animal vaccines and improve the level of post-exposure prophylaxis.
- 13 September 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-9
Open AccessEpidemiological characteristics of human rabies cases reported by sites in China from 2006 to 2022
Rabies is an incessant public health threat in China. The Ministry of Health implemented the Central Payment for Rabies Prevention and Control Project to assist with rabies prevention and control in a few representative provinces in 2006. Data on human rabies cases reported by the National Infectious Disease Reporting Information Management System and national surveillance sites from 2006 to 2022 were collected, and statistical and multivariate analyses were then used to assess the effectiveness of current prevention and control efforts. During 2006–2022, a total of 2025 human rabies cases were collected by the national surveillance sites, with incidence rates far above the national average, but the incidence rate was consistent with the national trend. Human rabies cases demonstrated a dual peak distribution in terms of exposure and onset dates, with the peak exposure dates falling mostly in the spring and summer and the peak onset dates occurring mostly in the summer and autumn. Three danger categories are shown by the geographical distribution: high, medium and low. Dogs had a high infection rate (86.93%), with own domesticated dogs accounting for the majority of infections. The rates of post-exposure prophylaxis are not constant. The median incubation period was 71 days. Various measures and policies implemented by the government have played a key role in reducing the incidence of rabies. To effectively prevent and control the resurgence of epidemics and halt the spread of the virus among host animals, it is imperative to prioritize and implement a robust dog management system, accelerate research and development of animal vaccines and improve the level of post-exposure prophylaxis.
- Open Access
- 10 November 2023
- Published by Springer Nature in Virology Journal
- Vol. 20 (1) , 1-15
Bardoxolone methyl inhibits the infection of rabies virus via Nrf2 pathway activation in vitro
Background: Rabies is a widespread, fatal, infectious disease. Several antivirals against rabies virus (RABV) infection have been reported, but no approved, RABV-specific antiviral drugs that inhibit RABV infection in the clinic after symptom onset are available. Therefore, more effective drugs to reduce rabies fatalities are urgently needed. Bardoxolone methyl (CDDO-Me), an FDA-approved compound that has long been known as an antioxidant inflammatory modulator and one of the most potent nuclear factor erythroid-derived 2-like 2 (Nrf2) activators, protects myelin, axons, and CNS neurons by Nrf2 activation. Therefore, we investigated the potency of its anti-RABV activity in vitro. Methods: The mouse neuroblastoma cell line Neuro2a (N2a) and three RABV strains of different virulence were used; the cytotoxicity and anti-RABV activity of CDDO-Me in N2a cells were evaluated by CCK-8 assay and direct fluorescent antibody (DFA) assay. Pathway activation in N2a cells infected with the RABV strains SC16, CVS-11 or CTN upon CDDO-Me treatment was evaluated by western blotting (WB) and DFA assay. Results: CDDO-Me significantly inhibited infection of the three RABV strains of differing virulence (SC16, CVS-11 and CTN) in N2a cells. We also examined whether CDDO-Me activates the Nrf2-associated pathway upon infection with RABV strains of differing virulence. Nrf2, phosphorylated sequestosome (SQSTM1), SQSTM1, hemoglobin oxygenase (HO-1) and NAD(P)H dehydrogenase quinone 1 (NQO1) expression in N2a cells increased to varying degrees with CDDO-Me treatment, accompanied by Kelch-like ECH-associated protein 1 (Keap1) dissociation, upon infection with SC16, CVS-11 or CTN. The activation of SQSTM1 phosphorylation was significantly associated with the degradation of Keap-1 in CDDO-Me-treated N2a cells upon RABV infection. Furthermore, N2a cells pretreated with the Nrf2-specific inhibitor ATRA showed a significant decrease in HO-1 and NQO1 expression and a decrease in the anti-RABV efficacy of CDDO-Me. These inhibitory effects were observed upon infection with three RABV strains of differing virulence. Conclusion: CDDO-Me inhibited RABV infection via Nrf2 activation, promoting a cytoprotective defense response in N2a cells. Our study provides a therapeutic strategy for RABV inhibition and neuroprotection during viral infection.
- 10 November 2023
- Published by Springer Nature in Virology Journal
- Vol. 20 (1) , 1-15
Open AccessBardoxolone methyl inhibits the infection of rabies virus via Nrf2 pathway activation in vitro
Background: Rabies is a widespread, fatal, infectious disease. Several antivirals against rabies virus (RABV) infection have been reported, but no approved, RABV-specific antiviral drugs that inhibit RABV infection in the clinic after symptom onset are available. Therefore, more effective drugs to reduce rabies fatalities are urgently needed. Bardoxolone methyl (CDDO-Me), an FDA-approved compound that has long been known as an antioxidant inflammatory modulator and one of the most potent nuclear factor erythroid-derived 2-like 2 (Nrf2) activators, protects myelin, axons, and CNS neurons by Nrf2 activation. Therefore, we investigated the potency of its anti-RABV activity in vitro. Methods: The mouse neuroblastoma cell line Neuro2a (N2a) and three RABV strains of different virulence were used; the cytotoxicity and anti-RABV activity of CDDO-Me in N2a cells were evaluated by CCK-8 assay and direct fluorescent antibody (DFA) assay. Pathway activation in N2a cells infected with the RABV strains SC16, CVS-11 or CTN upon CDDO-Me treatment was evaluated by western blotting (WB) and DFA assay. Results: CDDO-Me significantly inhibited infection of the three RABV strains of differing virulence (SC16, CVS-11 and CTN) in N2a cells. We also examined whether CDDO-Me activates the Nrf2-associated pathway upon infection with RABV strains of differing virulence. Nrf2, phosphorylated sequestosome (SQSTM1), SQSTM1, hemoglobin oxygenase (HO-1) and NAD(P)H dehydrogenase quinone 1 (NQO1) expression in N2a cells increased to varying degrees with CDDO-Me treatment, accompanied by Kelch-like ECH-associated protein 1 (Keap1) dissociation, upon infection with SC16, CVS-11 or CTN. The activation of SQSTM1 phosphorylation was significantly associated with the degradation of Keap-1 in CDDO-Me-treated N2a cells upon RABV infection. Furthermore, N2a cells pretreated with the Nrf2-specific inhibitor ATRA showed a significant decrease in HO-1 and NQO1 expression and a decrease in the anti-RABV efficacy of CDDO-Me. These inhibitory effects were observed upon infection with three RABV strains of differing virulence. Conclusion: CDDO-Me inhibited RABV infection via Nrf2 activation, promoting a cytoprotective defense response in N2a cells. Our study provides a therapeutic strategy for RABV inhibition and neuroprotection during viral infection.
- Open Access
- 14 July 2021
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 15 (7) , e0009527
Epidemiological and numerical simulation of rabies spreading from canines to various human populations in mainland China
Background: The mortality of humans due to rabies in China has been declining in recent years, but it is still a significant public health problem. According to the global framework, China strives to achieve the goal of eliminating human rabies before 2030. Methods: We reviewed the epidemiology of human deaths from rabies in mainland China from 2004 to 2018. We identified high risk regions, age and occupational groups, and used a continuous deterministic susceptibility-exposure-infection-recovery (SEIR) model with periodic transmission rate to explore seasonal rabies prevalence in different human populations. The SEIR model was used to simulate the data of human deaths from rabies reported by the Chinese Center for Disease Control and Prevention (China CDC). We calculated the relative transmission intensity of rabies from canines to different human groups, and they provided a reliable epidemiological basis for further control and prevention of human rabies. Results: Results showed that human deaths from rabies exhibited regional differences and seasonal characteristics in mainland China. The annual human death from rabies in different regions, age groups and occupational groups decreased steadily across time. Nevertheless, the decreasing rates and the calculated R0s of canines of various human groups were different. The transmission intensity of rabies from canines to human populations was the highest in the central regions of China, in people over 45 years old, and in farmers. Conclusions: Although the annual cases of human deaths from rabies have decreased steadily since 2007, the proportion of human deaths from rabies varies with region, age, gender, and occupation. Further enhancement of public awareness and immunization status in high-risk population groups and blocking the transmission routes of rabies from canines to humans are necessary. The concept of One Health should be abided and human, animal, and environmental health should be considered simultaneously to achieve the goal of eradicating human rabies before 2030.
- 14 July 2021
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 15 (7) , e0009527
Open AccessEpidemiological and numerical simulation of rabies spreading from canines to various human populations in mainland China
Background: The mortality of humans due to rabies in China has been declining in recent years, but it is still a significant public health problem. According to the global framework, China strives to achieve the goal of eliminating human rabies before 2030. Methods: We reviewed the epidemiology of human deaths from rabies in mainland China from 2004 to 2018. We identified high risk regions, age and occupational groups, and used a continuous deterministic susceptibility-exposure-infection-recovery (SEIR) model with periodic transmission rate to explore seasonal rabies prevalence in different human populations. The SEIR model was used to simulate the data of human deaths from rabies reported by the Chinese Center for Disease Control and Prevention (China CDC). We calculated the relative transmission intensity of rabies from canines to different human groups, and they provided a reliable epidemiological basis for further control and prevention of human rabies. Results: Results showed that human deaths from rabies exhibited regional differences and seasonal characteristics in mainland China. The annual human death from rabies in different regions, age groups and occupational groups decreased steadily across time. Nevertheless, the decreasing rates and the calculated R0s of canines of various human groups were different. The transmission intensity of rabies from canines to human populations was the highest in the central regions of China, in people over 45 years old, and in farmers. Conclusions: Although the annual cases of human deaths from rabies have decreased steadily since 2007, the proportion of human deaths from rabies varies with region, age, gender, and occupation. Further enhancement of public awareness and immunization status in high-risk population groups and blocking the transmission routes of rabies from canines to humans are necessary. The concept of One Health should be abided and human, animal, and environmental health should be considered simultaneously to achieve the goal of eradicating human rabies before 2030.
- Open Access
- 1 June 2021
- Published by Elsevier in Biosafety and Health
- Vol. 3 (3) , 142-147
Rabies surveillance and control in China over the last twenty years
- 1 June 2021
- Published by Elsevier in Biosafety and Health
- Vol. 3 (3) , 142-147
Open AccessRabies surveillance and control in China over the last twenty years
- Open Access
- 20 October 2020
- Published by Springer Nature in Virology Journal
- Vol. 17 (1) , 1-11
Inflammatory response and MAPK and NF-κB pathway activation induced by natural street rabies virus infection in the brain tissues of dogs and humans
Background: Street rabies virus (RABV) usually infects hosts at peripheral sites and migrates from motor or sensory nerves to the central nervous system. Several studies have found that inflammation is mild in a mouse model of street RABV infection. However, the pathogenetic mechanisms of street RABV in naturally infected dogs or humans are not well understood. Methods: Brain tissues collected from 3 dogs and 3 humans were used; these tissue samples were collected under the natural condition of rabies-induced death. The inflammatory response and pathway activation in the brain tissue samples of dogs and humans were evaluated by HE, IHC, ARY006, WB and ELISA. The clinical isolate street RABV strains CGS-17 and CXZ-15 from 30 six-week-old ICR mice were used to construct the mouse infection model presented here. Results: Neuronal degeneration and increased lymphocyte infiltration in the cerebral cortex, especially marked activation of microglia, formation of glial nodules, and neuronophagy, were observed in the dogs and humans infected with the street RABV strains. The various levels of proinflammatory chemokines, particularly CXCL1, CXCL12, CCL2, and CCL5, were increased significantly in the context of infection with street RABV strains in dogs and humans in relation to healthy controls, and the levels of MAPK and NF-κB phosphorylation were also increased in dogs and humans with natural infection. We also found that the degrees of pathological change, inflammatory response, MAPK and NF-κB signaling pathway activation were obviously increased during natural infection in dogs and humans compared with artificial model infection in mice. Conclusion: The data obtained here provide direct evidence for the RABV-induced activation of the inflammatory response in a dog infection model, which is a relatively accurate reflection of the pathogenic mechanism of human street RABV infection. These observations provide insight into the precise roles of underlying mechanisms in fatal natural RABV infection.
- 20 October 2020
- Published by Springer Nature in Virology Journal
- Vol. 17 (1) , 1-11
Open AccessInflammatory response and MAPK and NF-κB pathway activation induced by natural street rabies virus infection in the brain tissues of dogs and humans
Background: Street rabies virus (RABV) usually infects hosts at peripheral sites and migrates from motor or sensory nerves to the central nervous system. Several studies have found that inflammation is mild in a mouse model of street RABV infection. However, the pathogenetic mechanisms of street RABV in naturally infected dogs or humans are not well understood. Methods: Brain tissues collected from 3 dogs and 3 humans were used; these tissue samples were collected under the natural condition of rabies-induced death. The inflammatory response and pathway activation in the brain tissue samples of dogs and humans were evaluated by HE, IHC, ARY006, WB and ELISA. The clinical isolate street RABV strains CGS-17 and CXZ-15 from 30 six-week-old ICR mice were used to construct the mouse infection model presented here. Results: Neuronal degeneration and increased lymphocyte infiltration in the cerebral cortex, especially marked activation of microglia, formation of glial nodules, and neuronophagy, were observed in the dogs and humans infected with the street RABV strains. The various levels of proinflammatory chemokines, particularly CXCL1, CXCL12, CCL2, and CCL5, were increased significantly in the context of infection with street RABV strains in dogs and humans in relation to healthy controls, and the levels of MAPK and NF-κB phosphorylation were also increased in dogs and humans with natural infection. We also found that the degrees of pathological change, inflammatory response, MAPK and NF-κB signaling pathway activation were obviously increased during natural infection in dogs and humans compared with artificial model infection in mice. Conclusion: The data obtained here provide direct evidence for the RABV-induced activation of the inflammatory response in a dog infection model, which is a relatively accurate reflection of the pathogenic mechanism of human street RABV infection. These observations provide insight into the precise roles of underlying mechanisms in fatal natural RABV infection.